

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Therapeutic effects of Ginkgo biloba on ischemic manifestations of scleroderma in extremities

Protocol summary

Summary

The aim of this randomized double blind study is to assess the effect of Ginkgo biloba on the ischemic manifestations of scleroderma in extremities. A total of fifty patients with scleroderma and raynaud's phenomenon will be randomly assigned into two groups of 25 each. The patients in one group will receive Ginkgo biloba (Tolidaru Pharmaceutical Company) 40mg tds for 3 months while in control group will receive placebo. Raynaud's Condition Score and Score Modified Rodnan Skin will be evaluated at the end of months 1, 2, and 3 and compared between groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201103062053N1**
Registration date: **2011-03-06, 1389/12/15**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2011-03-06, 1389/12/15

Registrant information

Name

Seideh Zahra Mirfeizi

Name of organization / entity

Mashhad University of Medical Sciences and Health Services

Country

Iran (Islamic Republic of)

Phone

+98 51 1846 1781

Email address

mirfeiziz@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for Research of Mashhad University of Medical Sciences and Health Services

Expected recruitment start date

2009-09-23, 1388/07/01

Expected recruitment end date

2011-06-20, 1390/03/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Therapeutic effects of Ginkgo biloba on ischemic manifestations of scleroderma in extremities

Public title

Therapeutic effects of Ginkgo biloba on ischemic manifestations of scleroderma in extremities

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: suffering from scleroderma, suffering from Raynaud's phenomenon, primary level of education, age more than 18 and less than 50 years old, signing the informed consent Exclusion criteria: consumption of use anticoagulants, consumption of NSAIDs, consumption of mono amino Oxidase inhibitors

Age

From **18 years** old to **50 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 50

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Mashhad University of Medical Sciences and Health Services

Street address

Ghoreishi Building, Daneshgah St, PO Box:951

City

Mashhad

Postal code**Approval date**

2009-01-28, 1387/11/09

Ethics committee reference number

87176

Health conditions studied**1****Description of health condition studied**

Scleroderma

ICD-10 code

M34

ICD-10 code description

Progressive Systemic Sclerosis

Primary outcomes**1****Description**

Stiffness of the skin

Timepoint

Every months till 3 month

Method of measurement

Modified Rodnan Skin Score

2**Description**

Raynaud's Condition

Timepoint

before treatment and at the end of months 1 , 2 , 3

Method of measurement

Raynaud's Condition Score

Secondary outcomes**1****Description**

Interval of Raynaud's attack

Timepoint

every month till 3 month

Method of measurement

Patient examination and his/her statement about the condition of his/ her sickness.

Intervention groups**1****Description**

Ginkgo biloba, Oral Tab 40 mg, Tds , for 3 months

Category

Treatment - Drugs

2**Description**

Placebo, Oral Tab , Tds , for 3 months

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Emam Reza Hospital

Full name of responsible person**Street address****City**

Mashhad

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Vice Chancellor for Research of Mashhad University of Medical Sciences and Health Services

Full name of responsible person

Vice President for Research (Jalil Tavakol Afshari Ph.D.)

Street address

Ghoreishi Building, Daneshgah St, PO Box:951

City

Mashhad

Grant name

Grant code / Reference number**Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice Chancellor for Research of Mashhad University of Medical Sciences and Health Services

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Mashhad University of Medical Sciences and Health Services

Full name of responsible person

Mohamad Hassan Jokar

Position

Associated Professor/Sub-specialty in Rheumatology

Other areas of specialty/work**Street address**

Ghoreishi Building, Daneshgah St, PO Box:951

City

Mashhad

Postal code**Phone**

+98 51 1859 5818

Fax**Email**

jokarmh@mums.ac.ir

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Mashhad University of Medical Sciences and Health Services

Full name of responsible person

Mohamad Hassan Jokar

Position

Associate Professor/Sub-specialty in Rheumatology

Other areas of specialty/work**Street address**

Ghoreishi Building, Daneshgah St, PO Box:951

City

Mashhad

Postal code**Phone**

+98 51 1859 5818

Fax**Email**

jokarmh@mums.ac.ir

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Mashhad University of Medical Sciences and Health Services

Full name of responsible person

Seideh Zahra Mirfeizi

Position

Assistant Professor/Sub-specialty in Rheumatology

Other areas of specialty/work**Street address**

Ghoreishi Building, Daneshgah St, PO Box:951

City

Mashhad

Postal code**Phone****Fax****Email**

mirfeiziz@mums.ac.ir

Web page address**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty